RP
MIRM icon

Repertoire Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Repertoire Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-49,900
Closed -$1.2M – 21
2023
Q1 		$1.2M Buy
+49,900
New +$1.14M 0.35% 20

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Repertoire Partners's MIRM Position: Q2 2023 in Review

Repertoire Partners sold out of Mirum Pharmaceuticals (MIRM) in Q2 2023, closing a stake of 49,900 shares — an estimated $1.2M sold.

Repertoire Partners first reported a position in MIRM in Q1 2023 and held it in 1 quarter. The position peaked at $1.2M in Q1 2023. 146 funds tracked by Wall St. Rank hold MIRM as of Q2 2023.

  • Repertoire Partners reported no remaining Mirum Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Repertoire Partners sold 49,900 Mirum Pharmaceuticals shares in Q2 2023, an estimated $1.2M.
  • Repertoire Partners first reported a position in Mirum Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Repertoire Partners's Mirum Pharmaceuticals position peaked at $1.2M in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2023.

Based on Repertoire Partners's 13F filing for Q2 2023, filed 14 Aug 2023.